Spots Global Cancer Trial Database for DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
Official Title: Clinical Efficacy and Safety of DLAAG Protocol in the Treatment of Refractory/Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess: a Multicenter, Single-arm, Prospective Clinical Study
Study ID: NCT03356080
Study Description
Brief Summary: The purpose of this study is to evaluate of the clinical efficacy and safety of DLAAG protocol in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome with blast excess
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Friendship Hospital, Beijing, , China
Fujian Medical University Union Hospital, Fuzhou, , China
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, , China
Shanghai Tong Ren hospital, Shanghai, , China
The center hospital of Shanghai Fengxian District, Shanghai, , China
First Affiliated Hospital of Zhengzhou University., Zhengzhou, , China
Contact Details
Name: Ligen Liu
Affiliation: Shanghai Tong Ren Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
